SPIROMICS Study of Early COPD Progression (SOURCE)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Massachusetts, Worcester
Study ID
NCT05033990
Status
Recruiting

Conditions

  • COPD, Early-Onset

Eligibility Criteria

Sex
ALL
Age
30 Years - 55 Years
Healthy Volunteers
Accepted

Study Details

This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers predictive of smokers that will develop COPD. * To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related questionnaires assessing medical history, smoke exposure and use, medication use, social and behavioral health, pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine samples, pulmonary function testing to determine function, sputum induction to provide a sputum sample for airway biospecimen analysis, and CT imaging of the lungs.

Key Dates

Start date
Sep 8, 2021
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Healthy Controls
    Participants with no smoking history (\< 100 cigarettes in lifetime); pre-bronchodilator FEV1/FVC ≥ 0.70; pre-bronchodilator FEV1 ≥ 80% predicted; and pre-bronchodilator FVC ≥ 80% predicted.
  • Arm: Gold 0
    Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted. GOLD stands for the Global initiative for Chronic Obstructive Lung Disease.
  • Arm: Preserved Ratio Impaired Spirometry (PRISm)
    Participants with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 \< 80% predicted.
  • Arm: GOLD 1 - 2
    Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 ≥ 50% predicted.

Primary Outcome Measure

PRM fSAD [ Time Frame: Year 2-5 ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35205
J. Michael Wells, MD
Michelle Williams
(205) 934-5555
J. Michael Wells, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic ArizonaScottsdaleArizona85259
Victor Ortega, MD, PhD
Temeka Simmons
(480) 301-9224
Victor Ortega, MD (PRINCIPAL_INVESTIGATOR)
University of California Los AngelesLos AngelesCalifornia90095
Igor Barjaktarevic, MD, PhD
Roslynn Marzan-McGill, CPT, CCRP
(310) 825-2616
Igor Barjaktarevic, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Prescott G. Woodruff, MD, MPH
415-479-3370
Devin Roberts
(628) 233-1233
Prescott G. Woodruff, MD, MPH (PRINCIPAL_INVESTIGATOR)
National Jewish HealthDenverColorado80206
Claudia Onofrei, MD
Grace Wessels
(303) 270-2418
Claudia Onofrei, MD (PRINCIPAL_INVESTIGATOR)
University of Illinois ChicagoChicagoIllinois60608
Jerry Krishnan, MD, PhD
Lauren Greene
(312) 996-1365
Jerry Krishnan, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of IowaIowa CityIowa52242
Alejandro Comellas, MD
Rimas Nemickas
(319) 353-8863
Alejandro Comellas, MD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins Bayview Medical CenterBaltimoreMaryland21224
Nadia Hansel, MD, MPH
Wendy Lorizio
(410) 550-2449
Nadia Hansel, MD, MPH (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48130
Meilan Han, MD, MPH
Crystal Cutlip
(734) 647-6399
Meilan Han, MD, MPH (PRINCIPAL_INVESTIGATOR)
Columbia UniversityNew YorkNew York10032
R. Graham Barr, MD, PhD
Ramaz Elsadig
(646) 859-9553
R. Graham Barr, MD, PhD (PRINCIPAL_INVESTIGATOR)
Weill Cornell Medical CenterNew YorkNew York10065
Robert J Kaner, MD
Kimberly Kerr
(646) 962-2730
Robert Kaner, MD (PRINCIPAL_INVESTIGATOR)
Wake ForestWinston-SalemNorth Carolina27104
Jessica Bon, MD
Ashlynn Brock
(336) 713-8550
Jessica Bon, MD (PRINCIPAL_INVESTIGATOR)
Temple UniversityPhiladelphiaPennsylvania10140
Nathaniel Marchetti, DO
Sheril George
(215) 707-1359
Nathaniel Marchetti, DO (PRINCIPAL_INVESTIGATOR)
University of UtahSalt Lake CityUtah84108
Robert Paine, MD
Martin Villegas
(801) 581-6496
Robert Paine, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL